The need for such an adjuvant is underscored by the many studies of malaria, HIV and TB and similar intracellular pathogens, demonstrating that protective immunity is mediated in part by T cells, particularly CD8+ T cells [8–13] and that viral-vectored vaccines have been shown to be potent inducers of the CD8+ T-cell response mediating protection [14–16]. Here, CD8A is linked to malaria.